Tolerability and efficacy of house dust mite AIT

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 66, Issue SUPPL. 95, 2011, Pages 55-56

  Mosbech, Holger ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Efficacy study; house dust mite allergy immunotherapy; tablet; therapeutic effect on asthma; tolerability studies

Indexed keywords

ALLERGY IMMUNOTHERAPY TABLET; ANTIALLERGIC AGENT; BUDESONIDE; CORTICOSTEROID; GRASS POLLEN VACCINE; PLACEBO; UNCLASSIFIED DRUG;

ARTICLE; ASTHMA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HOUSE DUST ALLERGY; HUMAN; MOUTH EDEMA; PRIORITY JOURNAL; SUBLINGUAL IMMUNOTHERAPY; THROAT TIGHTNESS; VOMITING;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ALLERGENS; ANIMALS; ASTHMA; CHILD; CHILD, PRESCHOOL; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; HUMANS; INJECTIONS, SUBCUTANEOUS; NEBULIZERS AND VAPORIZERS; PYROGLYPHIDAE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79958801873     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2011.02641.x     Document Type: Article

References (2)

1. Calderon M, Dige E, Groes L,. A house dust mite allergen immunotherapy tablet suitable for further clinical development: results from the first phase I tolerability trial. Allergy 2009; 64 (Suppl. 90):148.
2. Mosbech H, de Blay F, Deckelmann R, Korsgaard J, Malcus I, Pastorello EA, et al. Efficacy against asthma demonstrated for a house dust mite allergen immunotherapy tablet. Allergy 2009; 64 (Suppl. 90):184.